ID

23562

Descrizione

Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1); ODM derived from: https://clinicaltrials.gov/show/NCT00308139

collegamento

https://clinicaltrials.gov/show/NCT00308139

Keywords

versioni (1)
  1. 09/07/17 09/07/17 -
Titolare del copyright

Study Director: Lisa Porter, MD Amylin Pharmaceuticals, LLC.

Caricato su

9 luglio 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY-NC 3.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Type 2 Diabetes Mellitus NCT00308139

Inglese

Eligibility Type 2 Diabetes Mellitus NCT00308139

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
has type 2 diabetes mellitus treated with diet modification and exercise alone or in combination with a stable regimen of a combination of metformin, sulphonylureas, and thiazolidinediones for a minimum of 2 months at screening.
Descrizione

diabetes mellitus type 2 with diet modification, exercise, metformin, sulfonylureas, thiazolidinediones

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0011860
UMLS CUI [1,2]
C0086153
UMLS CUI [1,3]
C0015259
UMLS CUI [1,4]
C0025598
UMLS CUI [1,5]
C3653359
UMLS CUI [1,6]
C1257987
hemoglobin a1c (hba1c) of 7.1% to 11.0%, inclusive, at screening.
Descrizione

hba1c

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0019018
body mass index (bmi) of 25 kg/m2 to 45 kg/m2, inclusive, at screening.
Descrizione

bmi

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1305855
(for sub-study) currently participating in open ended assessment period of main study 2993 lar105
Descrizione

study participation

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2348568
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
has been previously exposed to exenatide (byetta®), exenatide lar, or any glucagon-like peptide-1 (glp-1) analog.
Descrizione

exenatide, glucagon-like peptide 1

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0167117
UMLS CUI [2]
C0061355
received any investigational drug or has participated in any type of clinical trial within 30 days prior to screening.
Descrizione

investigational drug, study participation

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0013230
UMLS CUI [2]
C2348568
has been treated, is currently treated, or is expected to require or undergo treatment with any of the following excluded medications:
Descrizione

excluded medications

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C2828389
alpha glucosidase inhibitor or meglitinide within 30 days of screening;
Descrizione

alpha glucosidase inhibitor, meglitinide

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3539108
UMLS CUI [2]
C0065880
insulin within 2 weeks prior to screening or insulin for longer than 1 week within 3 months of screening;
Descrizione

insulin

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021641
regular use (> 14 days) of drugs that directly affect gastrointestinal motility;
Descrizione

gastrointestinal motility affecting drugs

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0017184
regular use (> 14 days) of systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption;
Descrizione

systemic corticosteroids

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2825233
regular use (> 14 days) of medications with addictive potential such as opiates and opioids;
Descrizione

addictive drugs

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0813966
prescription or over-the-counter weight loss medications within 6 months of screening.
Descrizione

over-the-counter weight loss medication

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0013231
UMLS CUI [1,2]
C0376606
(for sub-study) subjects will be terminated from study who do not participate in the dual chamber pen substudy
Descrizione

study participation

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2348568
Ritorna all'inizio della pagina

Similar models

Eligibility Type 2 Diabetes Mellitus NCT00308139

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
diabetes mellitus type 2 with diet modification, exercise, metformin, sulfonylureas, thiazolidinediones
Item
has type 2 diabetes mellitus treated with diet modification and exercise alone or in combination with a stable regimen of a combination of metformin, sulphonylureas, and thiazolidinediones for a minimum of 2 months at screening.
boolean
C0011860 (UMLS CUI [1,1])
C0086153 (UMLS CUI [1,2])
C0015259 (UMLS CUI [1,3])
C0025598 (UMLS CUI [1,4])
C3653359 (UMLS CUI [1,5])
C1257987 (UMLS CUI [1,6])
hba1c
Item
hemoglobin a1c (hba1c) of 7.1% to 11.0%, inclusive, at screening.
boolean
C0019018 (UMLS CUI [1])
bmi
Item
body mass index (bmi) of 25 kg/m2 to 45 kg/m2, inclusive, at screening.
boolean
C1305855 (UMLS CUI [1])
study participation
Item
(for sub-study) currently participating in open ended assessment period of main study 2993 lar105
boolean
C2348568 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
exenatide, glucagon-like peptide 1
Item
has been previously exposed to exenatide (byetta®), exenatide lar, or any glucagon-like peptide-1 (glp-1) analog.
boolean
C0167117 (UMLS CUI [1])
C0061355 (UMLS CUI [2])
investigational drug, study participation
Item
received any investigational drug or has participated in any type of clinical trial within 30 days prior to screening.
boolean
C0013230 (UMLS CUI [1])
C2348568 (UMLS CUI [2])
excluded medications
Item
has been treated, is currently treated, or is expected to require or undergo treatment with any of the following excluded medications:
boolean
C0013227 (UMLS CUI [1,1])
C2828389 (UMLS CUI [1,2])
alpha glucosidase inhibitor, meglitinide
Item
alpha glucosidase inhibitor or meglitinide within 30 days of screening;
boolean
C3539108 (UMLS CUI [1])
C0065880 (UMLS CUI [2])
insulin
Item
insulin within 2 weeks prior to screening or insulin for longer than 1 week within 3 months of screening;
boolean
C0021641 (UMLS CUI [1])
gastrointestinal motility affecting drugs
Item
regular use (> 14 days) of drugs that directly affect gastrointestinal motility;
boolean
C0013227 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0017184 (UMLS CUI [1,3])
systemic corticosteroids
Item
regular use (> 14 days) of systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary steroids known to have a high rate of systemic absorption;
boolean
C2825233 (UMLS CUI [1])
addictive drugs
Item
regular use (> 14 days) of medications with addictive potential such as opiates and opioids;
boolean
C0813966 (UMLS CUI [1])
over-the-counter weight loss medication
Item
prescription or over-the-counter weight loss medications within 6 months of screening.
boolean
C0013231 (UMLS CUI [1,1])
C0376606 (UMLS CUI [1,2])
study participation
Item
(for sub-study) subjects will be terminated from study who do not participate in the dual chamber pen substudy
boolean
C2348568 (UMLS CUI [1])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial